Anti-Diabetes Drugs - Tunisia

Tunisia

In Tunisia, the revenue in the Anti-Diabetes Drugs market is expected to reach US$28.08m by 2024.
Looking ahead, it is projected to exhibit a compound annual growth rate (CAGR 2024-2029) of 6.69%, leading to a market volume of US$38.81m by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$37,840.00m in 2024.
Tunisia's market for anti-diabetes drugs is witnessing a surge in demand due to the growing prevalence of diabetes in the country.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in Tunisia is experiencing steady growth in recent years.

Customer preferences: Tunisian customers are becoming more health-conscious and aware of the risks of diabetes, leading to an increased demand for anti-diabetes drugs. Additionally, the aging population in Tunisia is also contributing to the growth of the market.

Trends in the market: The trend in the Anti-Diabetes Drugs market in Tunisia is shifting towards more innovative and effective drugs. The market is experiencing a shift from traditional oral drugs to injectable drugs, which are more effective in managing diabetes. The market is also witnessing an increase in the use of combination therapies, which provide better glycemic control and reduce the risk of side effects.

Local special circumstances: Tunisia has a high prevalence of diabetes, with an estimated 15% of the population affected by the disease. This has led to a significant demand for anti-diabetes drugs in the country. Additionally, the Tunisian government has implemented several initiatives to improve diabetes management, such as the National Program for the Prevention and Control of Diabetes and the establishment of diabetes clinics.

Underlying macroeconomic factors: The Tunisian economy has been growing steadily in recent years, which has contributed to the growth of the Anti-Diabetes Drugs market. However, the market is also facing challenges such as high drug prices and limited access to healthcare in certain regions. The government's efforts to improve healthcare infrastructure and increase access to affordable drugs are expected to drive the growth of the market in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.